{"certainAgreement":{"piSponsorEmployee":true},"limitationsAndCaveats":{"description":"The study was terminated during a pending major amendment after interim analysis and until the FDA mandate of the discontinuation of any combination therapy of MK-3475 and lenalidomide."},"pointOfContact":{"email":"pawarode@umich.edu","organization":"University of Michigan Comprehensive Cancer Center","phone":"734-936-8785","title":"Dr. Attaphol Pawarode, M.D."}}